Clinical Trials Browser

Interventional × dostarlimab × 30 days × Clear all

NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT06062420 2026-04-09

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03680508 2026-04-02

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06567782 2026-04-02

AZUR-4

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT05277051 2026-03-23

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms